Tumor 5-fu-related mRNA expression and efficacy of oral fluoropyrimidines in adjuvant chemotherapy of colorectal cancer

Keiji Koda; Hideaki Miyauchi; Chihiro Kosugi; Takashi Kaiho; Nobuhiro Takiguchi; Susumu Kobayashi; Takashi Maruyama; Hisahiro Matsubara

doi:10.21873/anticanres.11105

Tumor 5-fu-related mRNA expression and efficacy of oral fluoropyrimidines in adjuvant chemotherapy of colorectal cancer

Keiji Koda, Hideaki Miyauchi, Chihiro Kosugi, Takashi Kaiho, Nobuhiro Takiguchi, Susumu Kobayashi, Takashi Maruyama, Hisahiro Matsubara

School of Medicine

Research output: Contribution to journal › Article › peer-review

6 Scopus citations

Abstract

Background: It has not been elucidated whether the clinical efficacy of oral fluoropyrimidines for adjuvant chemotherapy of colorectal cancer varies with tumor biological characteristics. Patients and Methods: A multicenter randomized trial was performed comparing oral tegafur/gimeracil/oteracil (S-1) and uracil-tegafur/ leucovorin (UFT/LV) as adjuvant therapy for stage III colorectal cancer. Postoperative survival was compared based on the 5-FUrelated mRNA levels in cancer tissues. Results: Among patients with tumor expressing dihydropyrimidine dehydrogenase (DPD) mRNA within the 66.7th percentile (lower 2/3) of all cases, overall survival (OS) was significantly better in the S-1 than in the UFT/LV group. In the S-1 group, patients with low DPD-expressing tumors had significantly better OS than those with highly expressing tumors. Patients with low thymidine synthase (TS)-expressing tumors had significantly better OS than those with highly expressing tumors. Conclusion: The efficacy of oral fluoropyrimidines as adjuvant chemotherapy for colorectal cancer may be influenced by the level of 5-FUrelated mRNA in cancer tissues.

Original language	English
Pages (from-to)	5325-5331
Number of pages	7
Journal	Anticancer Research
Volume	36
Issue number	10
DOIs	https://doi.org/10.21873/anticanres.11105
State	Published - Oct 2016

Keywords

5-FU-metabolizing enzyme
Adjuvant therapy
Colon cancer
Dihydropyrimidine dehydrogenase
Leucovorin
Rectal cancer
S-1
Thymidine synthase
Uracil-tegafur

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.21873/anticanres.11105

Cite this

@article{e9b2a688414e4f52a8bed20e63ba02b7,

title = "Tumor 5-fu-related mRNA expression and efficacy of oral fluoropyrimidines in adjuvant chemotherapy of colorectal cancer",

abstract = "Background: It has not been elucidated whether the clinical efficacy of oral fluoropyrimidines for adjuvant chemotherapy of colorectal cancer varies with tumor biological characteristics. Patients and Methods: A multicenter randomized trial was performed comparing oral tegafur/gimeracil/oteracil (S-1) and uracil-tegafur/ leucovorin (UFT/LV) as adjuvant therapy for stage III colorectal cancer. Postoperative survival was compared based on the 5-FUrelated mRNA levels in cancer tissues. Results: Among patients with tumor expressing dihydropyrimidine dehydrogenase (DPD) mRNA within the 66.7th percentile (lower 2/3) of all cases, overall survival (OS) was significantly better in the S-1 than in the UFT/LV group. In the S-1 group, patients with low DPD-expressing tumors had significantly better OS than those with highly expressing tumors. Patients with low thymidine synthase (TS)-expressing tumors had significantly better OS than those with highly expressing tumors. Conclusion: The efficacy of oral fluoropyrimidines as adjuvant chemotherapy for colorectal cancer may be influenced by the level of 5-FUrelated mRNA in cancer tissues.",

keywords = "5-FU-metabolizing enzyme, Adjuvant therapy, Colon cancer, Dihydropyrimidine dehydrogenase, Leucovorin, Rectal cancer, S-1, Thymidine synthase, Uracil-tegafur",

author = "Keiji Koda and Hideaki Miyauchi and Chihiro Kosugi and Takashi Kaiho and Nobuhiro Takiguchi and Susumu Kobayashi and Takashi Maruyama and Hisahiro Matsubara",

year = "2016",

month = oct,

doi = "10.21873/anticanres.11105",

language = "英語",

volume = "36",

pages = "5325--5331",

journal = "Anticancer Research",

issn = "0250-7005",

publisher = "International Institute of Anticancer Research",

number = "10",

}

TY - JOUR

T1 - Tumor 5-fu-related mRNA expression and efficacy of oral fluoropyrimidines in adjuvant chemotherapy of colorectal cancer

AU - Koda, Keiji

AU - Miyauchi, Hideaki

AU - Kosugi, Chihiro

AU - Kaiho, Takashi

AU - Takiguchi, Nobuhiro

AU - Kobayashi, Susumu

AU - Maruyama, Takashi

AU - Matsubara, Hisahiro

PY - 2016/10

Y1 - 2016/10

N2 - Background: It has not been elucidated whether the clinical efficacy of oral fluoropyrimidines for adjuvant chemotherapy of colorectal cancer varies with tumor biological characteristics. Patients and Methods: A multicenter randomized trial was performed comparing oral tegafur/gimeracil/oteracil (S-1) and uracil-tegafur/ leucovorin (UFT/LV) as adjuvant therapy for stage III colorectal cancer. Postoperative survival was compared based on the 5-FUrelated mRNA levels in cancer tissues. Results: Among patients with tumor expressing dihydropyrimidine dehydrogenase (DPD) mRNA within the 66.7th percentile (lower 2/3) of all cases, overall survival (OS) was significantly better in the S-1 than in the UFT/LV group. In the S-1 group, patients with low DPD-expressing tumors had significantly better OS than those with highly expressing tumors. Patients with low thymidine synthase (TS)-expressing tumors had significantly better OS than those with highly expressing tumors. Conclusion: The efficacy of oral fluoropyrimidines as adjuvant chemotherapy for colorectal cancer may be influenced by the level of 5-FUrelated mRNA in cancer tissues.

AB - Background: It has not been elucidated whether the clinical efficacy of oral fluoropyrimidines for adjuvant chemotherapy of colorectal cancer varies with tumor biological characteristics. Patients and Methods: A multicenter randomized trial was performed comparing oral tegafur/gimeracil/oteracil (S-1) and uracil-tegafur/ leucovorin (UFT/LV) as adjuvant therapy for stage III colorectal cancer. Postoperative survival was compared based on the 5-FUrelated mRNA levels in cancer tissues. Results: Among patients with tumor expressing dihydropyrimidine dehydrogenase (DPD) mRNA within the 66.7th percentile (lower 2/3) of all cases, overall survival (OS) was significantly better in the S-1 than in the UFT/LV group. In the S-1 group, patients with low DPD-expressing tumors had significantly better OS than those with highly expressing tumors. Patients with low thymidine synthase (TS)-expressing tumors had significantly better OS than those with highly expressing tumors. Conclusion: The efficacy of oral fluoropyrimidines as adjuvant chemotherapy for colorectal cancer may be influenced by the level of 5-FUrelated mRNA in cancer tissues.

KW - 5-FU-metabolizing enzyme

KW - Adjuvant therapy

KW - Colon cancer

KW - Dihydropyrimidine dehydrogenase

KW - Leucovorin

KW - Rectal cancer

KW - S-1

KW - Thymidine synthase

KW - Uracil-tegafur

UR - http://www.scopus.com/inward/record.url?scp=84991777591&partnerID=8YFLogxK

U2 - 10.21873/anticanres.11105

DO - 10.21873/anticanres.11105

M3 - 記事

C2 - 27798895

AN - SCOPUS:84991777591

SN - 0250-7005

VL - 36

SP - 5325

EP - 5331

JO - Anticancer Research

JF - Anticancer Research

IS - 10

ER -

Tumor 5-fu-related mRNA expression and efficacy of oral fluoropyrimidines in adjuvant chemotherapy of colorectal cancer

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this